SUMMARY

  • • The therapeutic application of RNAi machinery opened an innovative way for the treatment of some severe respiratory diseases.
  • • Delivery is the primary hurdle to translate this technique from lab to clinic.
  • • Polymer-, lipid-, and peptide-based nonviral siRNA delivery systems showed promising gene silencing capacity in vitro and in vivo.
  • • Challenges remain for the development of effective, safe, targeted, and stable delivery systems for siRNA therapeutic application.

REFERENCES

  • 1. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391 (6669), 806-811.
  • 2. Agrawal, N.; Dasaradhi, P. V. N.; Mohmmed, A.; Malhotra, P.; Bhatnagar, R. K.; Mukherjee, S. K., RNA interference: Biology, mechanism, and applications. Microbiology and Molecular Biology Reviews 2003, 67 (4), 657-685.
  • 3. Kumar, L. D.; Clarke, A. R., Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Advanced Drug Delivery Reviews 2007, 59 (2-3), 87-100.
  • 4. Kaiser, P. K.; Symons, R. C. A.; Shah, S. M.; Quinlan, E. J.; Tabandeh, H.; Do, D. V.; Reisen, G. et al., RNAi-based treatment for neovascular age-related macular degeneration by sirna-027. American Journal of Ophthalmology 2010, 150 (1), 33-39.e2.
  • 5. Merkel, O. M.; Rubinstein, I.; Kissel, T., siRNA delivery to the lung: What’s new? Advanced Drug Delivery Reviews 2014, 75, 112-128.
  • 6. Higuchi, Y.; Kawakami, S.; Hashida, M., Strategies for in vivo delivery of siRNAs recent progress. Biodrugs 2010, 24 (3), 195-205.
  • 7. Kumar, L. D.; Clarke, A. R., Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Advanced Drug Delivery Reviews 2007, 59 (2-3), 87-100.
  • 8. Merkel, O. M.; Kissel, T., Nonviral pulmonary delivery of siRNA. Accounts of Chemical Research 2012, 45 (7), 961-970.
  • 9. Garbuzenko, O. B.; Saad, M.; Betigeri, S.; Zhang, M.; Vetcher, A. A.; Soldatenkov, V. A.; Reimer, D. C.; Pozharov, V. P.; Minko, T., Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharmaceutical Research 2009, 26 (2), 382-394.
  • 10. Lam, J. K.-W.; Liang, W.; Chan, H.-K., Pulmonary delivery of therapeutic siRNA. Advanced Drug Delivery Reviews 2012, 64 (1), 1-15.
  • 11. Cun, D.; Wan, F.; Yang, M., Formulation strategies and particle engineering technologies for pulmonary delivery of biopharmaceuticals. Current Pharmaceutical Design 2015, 21 (19), 2599-2610.
  • 12. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik, S., Inhibition of respiratory viruses by nasally administered siRNA. Nature Medicine 2005, 11 (1), 50-55.
  • 13. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T., RNAi therapeutic platforms for lung diseases. Pharmaceuticals (Basel) 2013, 6 (2), 223-250.
  • 14. Brower, V., RNA interference advances to early-stage clinical trials. Journal of the National Cancer Institute 2010, 102 (19), 1459-1461.
  • 15. Steele, T. W.; Zhao, X.; Tarcha, P.; Kissel, T., Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery. European Journal of Pharmaceutics and Biopharmaceutics 2012, 80 (1), 14-24.
  • 16. Cun, D. M.; Jensen, D. K.; Maltesen, M. J.; Bunker, M.; Whiteside, P.; Scurr, D.; Foged, C.; Nielsen, H. M., High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. European Journal of Pharmaceutics and Biopharmaceutics 2011, 77 (1), 26-35.
  • 17. Rosenecker, J.; Naundorf, S.; Gersting, S. W.; Hauck, R. W.; Gessner, A.; Nicklaus, P.; Muller, R. H.; Rudolph, C., Interaction of bronchoalveolar lavage fluid with poly- plexes and lipoplexes: Analysing the role of proteins and glycoproteins. Journal of Gene Medicine 2003, 5 (1), 49-60.
  • 18. Raemdonck, K.; Vandenbroucke, R. E.; Demeester, J.; Sanders, N. N.; De Smedt, S. C., Maintaining the silence: Reflections on long-term RNAi. Drug Discovery Today 2008, 13 (21-22), 917-931.
  • 19. Di Gioia, S.; Conese, M., Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. Drug Design, Development and Therapy 2009, 2, 163-188.
  • 20. Gunther, M.; Lipka, J.; Malek, A.; Gutsch, D.; Kreyling, W.; Aigner, A., Poly- ethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2011, 77 (3), 438-449.
  • 21. Beyerle, A.; Merkel, O.; Stoeger, T.; Kissel, T., PEGylation affects cytotoxicity and cell- compatibility of poly(ethylene imine) for lung application: Structure-function relationships. Toxicology and Applied Pharmacology 2010, 242 (2), 146-154.
  • 22. Beyerle, A.; Braun, A.; Merkel, O.; Koch, F.; Kissel, T.; Stoeger, T., Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. Journal of Controlled Release: Official Journal of the Controlled Release Society 2011, 151 (1), 51-56.
  • 23. Kedinger, V.; Meulle, A.; Zounib, O.; Bonnet, M. E.; Gossart, J. B.; Benoit, E.; Messmer, M. et al., Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer 2013, 13, 338.
  • 24. Nielsen, E. J.; Nielsen, J. M.; Becker, D.; Karlas, A.; Prakash, H.; Glud, S. Z.; Merrison, J. et al., Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/ siRNA nanoparticles. Pharmaceutical Research 2010, 27 (12), 2520-2527.
  • 25. Okuda, T.; Kito, D.; Oiwa, A.; Fukushima, M.; Hira, D.; Okamoto, H., Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biological and Pharmaceutical Bulletin 2013, 36 (7), 1183-1191.
  • 26. Ghosn, B.; Singh, A.; Li, M.; Vlassov, A. V.; Burnett, C.; Puri, N.; Roy, K., Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 2010, 20 (3), 163-172.
  • 27. Noh, S. M.; Park, M. O.; Shim, G.; Han, S. E.; Lee, H. Y.; Huh, J. H.; Kim, M. S. et al., Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA. Journal of Controlled Release 2010, 145 (2), 159-164.
  • 28. Panyam, J.; Labhasetwar, V., Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews 2003, 55 (3), 329-347.
  • 29. Jensen, D. M.; Cun, D.; Maltesen, M. J.; Frokjaer, S.; Nielsen, H. M.; Foged, C., Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. Journal of Controlled Release 2010, 142 (1), 138-145.
  • 30. Jensen, D. K.; Jensen, L. B.; Koocheki, S.; Bengtson, L.; Cun, D. M.; Nielsen, H. M.; Foged, C., Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Journal of Controlled Release 2012, 157 (1), 141-148.
  • 31. Colombo, S.; Cun, D.; Remaut, K.; Bunker, M.; Zhang, J.; Martin-Bertelsen, B.; Yaghmur, A.; Braeckmans, K.; Nielsen, H. M.; Foged, C., Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles. Journal of Controlled Release 2015, 201, 22-31.
  • 32. Nguyen, J.; Steele, T. W.; Merkel, O.; Reul, R.; Kissel, T., Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. Journal of Controlled Release 2008, 132 (3), 243-251.
  • 33. Conti, D. S.; Brewer, D.; Grashik, J.; Avasarala, S.; da Rocha, S. R. P., Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Molecular Pharmaceutics 2014, 11 (6), 1808-1822.
  • 34. Griesenbach, U.; Kitson, C.; Escudero Garcia, S.; Farley, R.; Singh, C.; Somerton, L.; Painter, H. et al., Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respiratory Research 2006, 7, 26.
  • 35. Moschos, S. A.; Jones, S. W.; Perry, M. M.; Williams, A. E.; Erjefalt, J. S.; Turner, J. J.; Barnes, P. J.; Sproat, B. S.; Gait, M. J.; Lindsay, M. A., Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjugate Chemistry 2007, 18 (5), 1450-1459.
  • 36. Akinc, A.; Zumbuehl, A.; Goldberg, M.; Leshchiner, E. S.; Busini, V.; Hossain, N.; Bacallado, S. A. et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotechnology 2008, 26 (5), 561-569.
  • 37. Taratula, O.; Kuzmov, A.; Shah, M.; Garbuzenko, O. B.; Minko, T., Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. Journal of Controlled Release 2013, 171 (3), 349-357.
  • 38. Baoum, A.; Ovcharenko, D.; Berkland, C., Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. International Journal of Pharmaceutics 2012, 427 (1), 134-142.
  • 39. Fujita, Y.; Kuwano, K.; Ochiya, T., Development of small RNA delivery systems for lung cancer therapy. International Journal of Molecular Sciences 2015, 16 (3), 5254-5270.
  • 40. Mainelis, G.; Seshadri, S.; Garbuzenko, O. B.; Han, T.; Wang, Z.; Minko, T., Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2013, 26 (6), 345-354.
  • 41. Gandhi, N. S.; Tekade, R. K.; Chougule, M. B., Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. Journal of Controlled Release: Official Journal of the Controlled Release Society 2014, 0, 238-256.
  • 42. Tian, H.; Liu, S.; Zhang, J.; Zhang, S.; Cheng, L.; Li, C.; Zhang, X. et al., Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. Journal of Biomedical Nanotechnology 2012, 8 (4), 633-641.
  • 43. Xu, C.; Wang, P.; Zhang, J.; Tian, H.; Park, K.; Chen, X., Pulmonary codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer. Small 2015, 11 (34), 4321-4333.
  • 44. Fujita, Y.; Takeshita, F.; Mizutani, T.; Ohgi, T.; Kuwano, K.; Ochiya, T., A novel platform to enable inhaled naked RNAi medicine for lung cancer. Scientific Reports 2013, 3, 3325.
  • 45. Shim, G.; Choi, H. W.; Lee, S.; Choi, J.; Yu, Y. H.; Park, D. E.; Choi, Y.; Kim, C. W.; Oh, Y. K., Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Molecular Therapy: The Journal of the American Society of Gene Therapy 2013, 21 (4), 816-824.
  • 46. Hong, S. H.; Minai-Tehrani, A.; Chang, S. H.; Jiang, H. L.; Lee, S.; Lee, A. Y.; Seo, H. W.; Chae, C.; Beck, G. R., Jr.; Cho, M. H., Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis. PLOS ONE 2013, 8 (10), e77121.
  • 47. Conde, J.; Tian, F.; Hernandez, Y.; Bao, C.; Cui, D.; Janssen, K. P.; Ibarra, M. R.; Baptista, P. V.; Stoeger, T.; de la Fuente, J. M., In vivo tumor targeting via nanoparticle- mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013, 34 (31), 7744-7753.
  • 48. Taratula, O.; Garbuzenko, O. B.; Chen, A. M.; Minko, T., Innovative strategy for treatment of lung cancer: Targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. Journal of Drug Targeting 2011, 19 (10), 900-914.
  • 49. Jiang, H.-L.; Hong, S.-H.; Kim, Y.-K.; Islam, M. A.; Kim, H.-J.; Choi, Y.-J.; Nah, J.-W. et al., Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. International Journal of Pharmaceutics 2011, 420 (2), 256-265.
  • 50. Wang, C.; Ding, C.; Kong, M.; Dong, A.; Qian, J.; Jiang, D.; Shen, Z., Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochemical and Biophysical Research Communications 2011, 410 (3), 537-542.
  • 51. Han, J.; Wang, Q.; Zhang, Z.; Gong, T.; Sun, X., Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 2014, 10 (3), 524-535.
  • 52. Yu, H.; Zou, Y.; Jiang, L.; Yin, Q.; He, X.; Chen, L.; Zhang, Z.; Gu, W.; Li, Y., Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH- responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 2013, 34 (11), 2738-2747.
  • 53. Das, J.; Das, S.; Paul, A.; Samadder, A.; Bhattacharyya, S. S.; Khuda-Bukhsh, A. R., Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicology Letters 2014, 225 (3), 454-466.
  • 54. Yang, Y.; Li, J.; Liu, F.; Huang, L., Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Molecular Therapy 2012, 20 (3), 609-615.
  • 55. Cho, W.-Y.; Hong, S.-H.; Singh, B.; Islam, M. A.; Lee, S.; Lee, A. Y.; Gankhuyag, N. et al., Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. European Journal of Pharmaceutics and Biopharmaceutics 2015, 94, 450-462.
  • 56. Guo, C.; Al-Jamal, W. T.; Toma, F. M.; Bianco, A.; Prato, M.; Al-Jamal, K. T.; Kostarelos, K., Design of cationic multiwalled carbon nanotubes as efficient siRNA vectors for lung cancer xenograft eradication. Bioconjugate Chemistry 2015, 26 (7), 1370-1379.
  • 57. Zhu, X.; Xu, Y.; Solis, L. M.; Tao, W.; Wang, L.; Behrens, C.; Xu, X. et al., Long- circulating siRNA nanoparticles for validating prohibitinl-targeted non-small cell lung cancer treatment. Proceedings of the National Academy of Sciences of the United States of America 2015, 112 (25), 7779-7784.
  • 58. Fehring, V.; Schaeper, U.; Ahrens, K.; Santel, A.; Keil, O.; Eisermann, M.; Giese, K.; Kaufmann, J., Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Mol Ther 2014, 22 (4), 811-820.
  • 59. Zhang, Y.; Schwerbrock, N. M.; Rogers, A. B.; Kim, W. Y.; Huang, L., Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Molecular Therapy 2013, 21 (8), 1559-1569.
  • 60. Xia, L.; Guan, W.; Wang, D.; Zhang, Y.-S.; Zeng, L.-L.; Li, Z.-P.; Wang, G.; Yang, Z.-Z., Killing effect of Ad5/F35-APE1 siRNA recombinant adenovirus in combination with hematoporphrphyrin derivative-mediated photodynamic therapy on human nonsmall cell lung cancer. BioMedResearch International 2013, 2013, 957913.
 
Source
< Prev   CONTENTS   Source   Next >